Predicting Response to Neoadjuvant Chemotherapy Using Harmonic Motion Imaging in Women With Breast Cancer
Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
For this study, the investigators propose investigation of a new imaging technique, Harmonic Motion Imaging (HMI), and the evaluation of its potential role in prediction of breast cancer response to neoadjuvant chemotherapy (NACT). The investigators hypothesize that changes in HMI parameters will predict response to neoadjuvant systemic therapy in early-stage breast cancer.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:
• Women age ≥18
• Deemed eligible to receive neoadjuvant systemic therapy as per the treating physician, with the dose and schedule deemed appropriate by the treating physician.
• Any stage invasive breast cancer provided the primary breast tumor size is ≥ 4 mm
Locations
United States
New York
Columbia University Irving Medical Center/NYP
RECRUITING
New York
Contact Information
Primary
Elisa Konofagou, PhD
ek2191@columbia.edu
212-342-1612
Backup
Yangpei Liu, MSc
yl4786@columbia.edu
212-342-1612
Time Frame
Start Date: 2021-06-14
Estimated Completion Date: 2026-05
Participants
Target number of participants: 50
Treatments
Experimental: HMI Group
Women undergoing standard neoadjuvant chemotherapy for breast cancer
Related Therapeutic Areas
Sponsors
Leads: Columbia University
Collaborators: National Cancer Institute (NCI)